» Articles » PMID: 21826257

Contribution of Alanine-76 and Serine Phosphorylation in α-Synuclein Membrane Association and Aggregation in Yeasts

Overview
Journal Parkinsons Dis
Publisher Wiley
Date 2011 Aug 10
PMID 21826257
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

In Parkinson's disease (PD), misfolded and aggregated α-synuclein protein accumulates in degenerating midbrain dopaminergic neurons. The amino acid alanine-76 in α-synuclein and phosphorylation at serine-87 and serine-129 are thought to regulate its aggregation and toxicity. However, their exact contributions to α-synuclein membrane association are less clear. We found that α-synuclein is indeed phosphorylated in fission yeast and budding yeast, the two models that we employed for assessing α-synuclein aggregation and membrane association properties, respectively. Surprisingly, blocking serine phosphorylation (S87A, S129A, and S87A/S129A) or mimicking it (S87D, S129D) altered α-synuclein aggregation in fission yeast. Either blocking or mimicking this phosphorylation increased endomembrane association in fission yeast, but only mimicking it decreased plasma membrane association in budding yeast. Polar substitution mutations of alanine-76 (A76E and A76R) decreased α-synuclein membrane association in budding yeast and decreased aggregation in fission yeast. These yeast studies extend our understanding of serine phosphorylation and alanine-76 contributions to α-synuclein aggregation and are the first to detail their impact on α-synuclein's plasma membrane and endomembrane association.

Citing Articles

Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies.

Kawahata I, Finkelstein D, Fukunaga K Int J Mol Sci. 2022; 23(11).

PMID: 35682892 PMC: 9181156. DOI: 10.3390/ijms23116216.


Racemization in Post-Translational Modifications Relevance to Protein Aging, Aggregation and Neurodegeneration: Tip of the Iceberg.

Dyakin V, Wisniewski T, Lajtha A Symmetry (Basel). 2021; 13(3).

PMID: 34350031 PMC: 8330555. DOI: 10.3390/sym13030455.


Chronic α-Synuclein Accumulation in Rat Hippocampus Induces Lewy Bodies Formation and Specific Cognitive Impairments.

Kasongo D, de Leo G, Vicario N, Leanza G, Legname G eNeuro. 2020; 7(3).

PMID: 32393581 PMC: 7307628. DOI: 10.1523/ENEURO.0009-20.2020.


Lipids at the Crossroad of α-Synuclein Function and Dysfunction: Biological and Pathological Implications.

Alza N, Iglesias Gonzalez P, Conde M, Uranga R, Salvador G Front Cell Neurosci. 2019; 13:175.

PMID: 31118888 PMC: 6504812. DOI: 10.3389/fncel.2019.00175.


Are PARKIN patients ideal candidates for dopaminergic cell replacement therapies?.

Kunath T, Natalwala A, Chan C, Chen Y, Stecher B, Taylor M Eur J Neurosci. 2018; 49(4):453-462.

PMID: 30586214 PMC: 6492143. DOI: 10.1111/ejn.14314.


References
1.
Paleologou K, Oueslati A, Shakked G, Rospigliosi C, Kim H, Lamberto G . Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci. 2010; 30(9):3184-98. PMC: 2947449. DOI: 10.1523/JNEUROSCI.5922-09.2010. View

2.
Koo H, Lee H, Im H . Sequence determinants regulating fibrillation of human alpha-synuclein. Biochem Biophys Res Commun. 2008; 368(3):772-8. DOI: 10.1016/j.bbrc.2008.01.140. View

3.
Chen L, Feany M . Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci. 2005; 8(5):657-63. DOI: 10.1038/nn1443. View

4.
Spillantini M, Crowther R, Jakes R, Hasegawa M, Goedert M . alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A. 1998; 95(11):6469-73. PMC: 27806. DOI: 10.1073/pnas.95.11.6469. View

5.
Flower T, Clark-Dixon C, Metoyer C, Yang H, Shi R, Zhang Z . YGR198w (YPP1) targets A30P alpha-synuclein to the vacuole for degradation. J Cell Biol. 2007; 177(6):1091-104. PMC: 2064368. DOI: 10.1083/jcb.200610071. View